Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Future prospects for anti-cytokine treatment.

Literature DB >> 11053102

Future prospects for anti-cytokine treatment.

M Feldmann¹, J Miotla, E Paleolog, R Williams, A M Malfait, P Taylor, F M Brennan, R N Maini.

Abstract

The era of anti-cytokine treatment in rheumatology has just begun. The first generation therapeutic agents, biological agents that block tumour necrosis factor alpha such as monoclonal antibodies or receptor Ig fusion proteins are safe and effective, and so this has generated much interest in how to increase the benefit or deliver it more cost effectively. This article provides a personal view of the coming trends in anti-cytokine treatment. Which of these will be realised in the future will be of interest.

Entities: Disease

Mesh：

Substances：

Year: 2000 PMID： 11053102 PMCID： PMC1766620 DOI： 10.1136/ard.59.suppl_1.i119

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

31 in total

Review 1. How important are T cells in chronic rheumatoid synovitis?

Authors: G S Firestein; N J Zvaifler
Journal: Arthritis Rheum Date: 1990-06

Review 2. Manipulation of T-cell responses with monoclonal antibodies.

Authors: H Waldmann
Journal: Annu Rev Immunol Date: 1989 Impact factor: 28.527

3. A proinflammatory role for IL-18 in rheumatoid arthritis.

Authors: J A Gracie; R J Forsey; W L Chan; A Gilmour; B P Leung; M R Greer; K Kennedy; R Carter; X Q Wei; D Xu; M Field; A Foulis; F Y Liew; I B McInnes
Journal: J Clin Invest Date: 1999-11 Impact factor: 14.808

4. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation.

Authors: G Penna; L Adorini
Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422

5. Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis.

Authors: D H Manicourt; P Poilvache; A Van Egeren; J P Devogelaer; M E Lenz; E J Thonar
Journal: Arthritis Rheum Date: 2000-02

6. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.

Authors: R M Tuder; B E Flook; N F Voelkel
Journal: J Clin Invest Date: 1995-04 Impact factor: 14.808

7. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Authors: M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; P Katsikis; F M Brennan; J Walker; H Bijl; J Ghrayeb
Journal: Arthritis Rheum Date: 1993-12

8. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis.

Authors: A E Koch; L A Harlow; G K Haines; E P Amento; E N Unemori; W L Wong; R M Pope; N Ferrara
Journal: J Immunol Date: 1994-04-15 Impact factor: 5.422

9. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis.

Authors: R O Williams; L J Mason; M Feldmann; R N Maini
Journal: Proc Natl Acad Sci U S A Date: 1994-03-29 Impact factor: 11.205

10. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Authors: R A Fava; N J Olsen; G Spencer-Green; K T Yeo; T K Yeo; B Berse; R W Jackman; D R Senger; H F Dvorak; L F Brown
Journal: J Exp Med Date: 1994-07-01 Impact factor: 14.307

3 in total

Review 1. Appropriate and effective management of rheumatoid arthritis.

Authors: F C Breedveld; J R Kalden
Journal: Ann Rheum Dis Date: 2004-06 Impact factor: 19.103

2. Biological agents targeting beyond TNF-alpha.

Authors: Rashmi Sharma; Chaman Lal Sharma; Annil Mahajan
Journal: Indian J Crit Care Med Date: 2008-10

3. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection.

Authors: Yulia A Desheva; Galina F Leontieva; Tatiana A Kramskaya; Galina O Landgraf; Ivan A Sychev; Andrey R Rekstin; Alexander N Suvorov
Journal: Heliyon Date: 2019-02-05

3 in total